PU25.01 | Social disclosures in relation to perceived HIV protection provided by the dapivirine vaginal ring | Publication Only | Preclinical studies for HIV prevention |
PE25.01 | What women want in a multipurpose vaginal ring: findings from a phase 1 trial in the U.S. and the Dominican Republic | E-poster | Product acceptability and adherence |
PE25.02 | Impact of women's home environment on use of the dapivirine ring for HIV prevention in MTN-025/HOPE | E-poster | Product acceptability and adherence |
PE25.03 | Patterns of adherence among South African women in a phase III randomized controlled trial of a dapivirine vaginal ring for HIV-1 prevention | E-poster | Product acceptability and adherence |
PE25.05 | Utilization patterns and HIV incidence within the first year of initiation of FTC/TDF for HIV pre-exposure prophylaxis (PrEP) among insured persons in the US | E-poster | Product acceptability and adherence |
PE25.06 | PrEP adherence is associated with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe | E-poster | Product acceptability and adherence |
PE25.07 | End-users' hypothetical acceptability of a biodegradable implant to prevent HIV and unplanned pregnancy: qualitative insights from South Africa and Zimbabwe | E-poster | Product acceptability and adherence |
PE25.08 | PrEP use in the HVTN 702 HIV vaccine efficacy trial conducted in South Africa | E-poster | Product acceptability and adherence |
PE25.09 | Predictors of PrEP discontinuation and refill delays among over 47,000 clients first starting PrEP in Kenya, Lesotho and Tanzania: Implications for programs | E-poster | Product acceptability and adherence |
PE25.10 | 'Men will never take a pill every day if they don't have to': assumptions and realities around acceptability of PrEP among heterosexual men | E-poster | Product acceptability and adherence |